Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for ANDA 090101

Expand all

IRINOTECAN HYDROCHLORIDE (IRINOTECAN HYDROCHLORIDE)
40MG/2ML (20MG/ML)
Marketing Status: Prescription
Active Ingredient: IRINOTECAN HYDROCHLORIDE
Proprietary Name: IRINOTECAN HYDROCHLORIDE
Dosage Form; Route of Administration: INJECTABLE; INJECTION
Strength: 40MG/2ML (20MG/ML)
Reference Listed Drug: No
Reference Standard: No
TE Code: AP
Application Number: A090101
Product Number: 002
Approval Date: Feb 27, 2008
Applicant Holder Full Name: TEVA PHARMACEUTICALS USA
Marketing Status:  Prescription
Patent and Exclusivity Information
IRINOTECAN HYDROCHLORIDE (IRINOTECAN HYDROCHLORIDE)
100MG/5ML (20MG/ML)
Marketing Status: Prescription
Active Ingredient: IRINOTECAN HYDROCHLORIDE
Proprietary Name: IRINOTECAN HYDROCHLORIDE
Dosage Form; Route of Administration: INJECTABLE; INJECTION
Strength: 100MG/5ML (20MG/ML)
Reference Listed Drug: No
Reference Standard: No
TE Code: AP
Application Number: A090101
Product Number: 003
Approval Date: Feb 27, 2008
Applicant Holder Full Name: TEVA PHARMACEUTICALS USA
Marketing Status:  Prescription
Patent and Exclusivity Information
IRINOTECAN HYDROCHLORIDE (IRINOTECAN HYDROCHLORIDE)
500MG/25ML (20MG/ML)
Marketing Status: Prescription
Active Ingredient: IRINOTECAN HYDROCHLORIDE
Proprietary Name: IRINOTECAN HYDROCHLORIDE
Dosage Form; Route of Administration: INJECTABLE; INJECTION
Strength: 500MG/25ML (20MG/ML)
Reference Listed Drug: No
Reference Standard: No
TE Code: AP
Application Number: A090101
Product Number: 001
Approval Date: Nov 26, 2008
Applicant Holder Full Name: TEVA PHARMACEUTICALS USA
Marketing Status:  Prescription
Patent and Exclusivity Information

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English